Live from the NIH registry
Studies recruiting near Rockford right now
Top 25 of 110 recruiting studies, sorted by proximity — each links to its official registry page
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm
Phase 2
Interventional 70 participants sought
Mercyhealth Cancer Institute - Rockford — Rockford, Illinois (1.7 mi)
· Sponsor: National Cancer Institute (NCI)
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 3
Interventional 1,524 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Phase 3
Interventional 364 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: SWOG Cancer Research Network
The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.
Paroxysmal Atrial Fibrillation
N/A
Observational 250 participants sought
Mercy Health — Janesville, Wisconsin (29.3 mi)
· Sponsor: Heart Rhythm Clinical and Research Solutions, LLC
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Multiple conditions
Phase 2
Interventional 98 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: NRG Oncology
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2
Phase 2
Interventional 100 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: National Cancer Institute (NCI)
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack
Cardiovascular Risk, Acute Myocardial Infarction (AMI)
Phase 3
Interventional 10,000 participants sought
OSF HealthCare_Cardiovasc Inst — Rockford, Illinois (1.7 mi)
· Sponsor: Novo Nordisk A/S
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
N/A
Observational 2,000 participants sought
OSF Saint Anthony Medical Center — Rockford, Illinois (1.7 mi)
· Sponsor: Wake Forest University Health Sciences
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Phase 3
Interventional 1,160 participants sought
Research Site — Rockford, Illinois (1.7 mi)
· Sponsor: AstraZeneca
A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System
Atrial Fibrillation
N/A
Interventional 276 participants sought
Mercy Hospital — Janesville, Wisconsin (29.3 mi)
· Sponsor: Biosense Webster, Inc.
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
Phase 3
Interventional 3,680 participants sought
OSF Saint Anthony Medical Center — Rockford, Illinois (1.7 mi)
· Sponsor: National Cancer Institute (NCI)
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Phase 2, Phase 3
Interventional 613 participants sought
UW Health Carbone Cancer Center Rockford — Rockford, Illinois (1.7 mi)
· Sponsor: National Cancer Institute (NCI)
Parent SMART (Substance Misuse in Adolescents in Residential Treatment)
Substance Use, Adolescent Behavior
N/A
Interventional 220 participants sought
Rosecrance Health Network — Rockford, Illinois (1.7 mi)
· Sponsor: Brown University
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Malignant Solid Neoplasm
N/A
Observational 2,062 participants sought
SSM Health Dean Medical Group - Janesville — Janesville, Wisconsin (29.3 mi)
· Sponsor: SWOG Cancer Research Network
Reaching Rural Cancer Survivors Who Smoke Using Text-Based Program
Cigarette Smoking-Related Carcinoma
Phase 3
Interventional 600 participants sought
OSF Saint Anthony Medical Center — Rockford, Illinois (1.7 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Non-small Cell Lung Cancer
Phase 3
Interventional 320 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: Canadian Cancer Trials Group
Implementing Contingency Management for Stimulant Use in Specialty Addiction Treatment Organizations
Stimulant Use (Diagnosis)
N/A
Interventional 76 participants sought
Rosecrance Health Network — Rockford, Illinois (1.7 mi)
· Sponsor: Northwestern University
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8
Phase 3
Interventional 1,100 participants sought
UW Health Carbone Cancer Center Rockford — Rockford, Illinois (1.7 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma
Phase 3
Interventional 336 participants sought
UW Health Carbone Cancer Center Rockford — Rockford, Illinois (1.7 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma
Phase 2
Interventional 170 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Effectiveness of an Automated Falls-Risk Screening and Referral Tool in the Emergency Department (ED)
Falls-Risk
N/A
Observational 30,000 participants sought
Swedish American Emergency Department — Rockford, Illinois (1.7 mi)
· Sponsor: University of Wisconsin, Madison
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype
Phase 2
Interventional 900 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: SWOG Cancer Research Network
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
Pancreatic Neoplasm
N/A
Observational 770 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma
Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
Phase 3
Interventional 398 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: NRG Oncology
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Cutaneous Melanoma, Stage II
N/A
Interventional 2,998 participants sought
Northwestern Medicine Cancer Center Kishwaukee — DeKalb, Illinois (27.9 mi)
· Sponsor: Melanoma and Skin Cancer Trials Limited